University Research Lecturer
Helen Dakin joined the Health Economics Research Centre in February 2008. Before starting at HERC, she worked at Abacus International and completed her MSc in Economic Evaluation in Healthcare at City University. She previously graduated from Cambridge University with Masters and Bachelor's degrees in Biochemistry. In 2014, she completed a DPhil at the University of Oxford on the optimal methods for conducting economic evaluations of factorial clinical trials.
Her current projects include: the STAR trial, which evaluates radiotherapy alongside bevacizumab (Avastin) in age-related macular degeneration; the ACHE study, which evaluates clinical tools and thresholds for selecting patients for joint replacement; and the KAT trial, which assesses the cost-effectiveness of different types of knee replacement component.
Research paper on factors influencing NICE decisions available here.
Cost-effectiveness of adalimumab for early-stage Dupuytren's disease : an economic evaluation based on a randomized controlled trial and individual-patient simulation model.
Dakin H. et al, (2022), Bone Jt Open, 3, 898 - 906
Corrigendum: Progressive exercise compared with best-practice advice, with or without corticosteroid injection, for rotator cuff disorders: the GRASP factorial RCT.
Hopewell S. et al, (2022), Health Technol Assess, 25, 159 - 160
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial
Nanchahal J. et al, (2022), The Lancet Rheumatology, 4, e407 - e416
Early-stage Dupuytren's disease treatment; a promising next step?
Selles R., (2022), The Lancet Rheumatology, 4, e377 - e378
Moulded cast compared with K-wire fixation after manipulation of an acute dorsally displaced distal radius fracture: the DRAFFT 2 RCT
Costa ML. et al, (2022), Health Technology Assessment, 26, 1 - 80